NGF and Alzheimer disease: Previous preclinical studies and pilot trials have shown that the intranasal administration of NGF (Tuszynski et al., 2015) and insulin (Craft et al., 2012) to mild cognitive impairment (MCI) and early AD patients was safe and resulted in rapid improvement of cognition, even within 30 min upon nasal sniffing.